A5032713092- Estrogen and related hormone effects
- Nutrition, Genetics, and Disease
- Breast Cancer Treatment Studies
- Cancer Risks and Factors
- Gene expression and cancer classification
- Genetic factors in colorectal cancer
- Breast Lesions and Carcinomas
- Ovarian cancer diagnosis and treatment
- Cancer Cells and Metastasis
- Breast Implant and Reconstruction
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cancer Diagnosis and Treatment
- Endometriosis Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Pediatric Urology and Nephrology Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Urinary Tract Infections Management
- Diet and metabolism studies
- Cervical Cancer and HPV Research
- Uterine Myomas and Treatments
- Cytokine Signaling Pathways and Interactions
- Thyroid Cancer Diagnosis and Treatment
- Reproductive System and Pregnancy
- Metabolism, Diabetes, and Cancer
University of Turin
2002-2025
Ospedale Sant'Anna
2004-2023
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
2022
Presidio Ospedaliero
2017
Ospedale Sant'Anna
2016
St. Anna Hospital
2012
Santa Maria Nuova Hospital
2009
Policlinico S.Orsola-Malpighi
2007
University of Cagliari
2005
University of Messina
2005
Tamoxifen, which is actually the gold standard adjuvant treatment in estrogen receptor-positive early breast cancer, associated with an increased risk of endometrial cancer and other life-threatening events. Moreover, many women relapse during or after tamoxifen therapy because development resistance. Therefore new approaches are required.We conducted a prospective randomized trial to test efficacy switching postmenopausal patients who were already receiving aromatase inhibitor anastrozole....
Sentinel lymph node biopsy (SLNB) is the standard of care for axillary staging patients with early breast cancer (BC), but its necessity can be questioned since surgery examination nodes not performed curative intent.
526 Background: We have previously shown that switching to ANA after 2–3 years of TAM is well tolerated and significantly improves event-free (EFS) progression-free survival (PFS) postmenopausal ebc (Breast Cancer Res Treat 82, 2003). Here we report on an additional analysis at a median follow-up time 52 mos (1–80 mos). Methods: This was open phase III trial comparing 5 vs followed by 3–2 (total duration treatment: years). PFS the primary end point. EFS, OS safety were secondary points....
Abstract Purpose: Our goal was to examine a panel of 11 biochemical variables, measured in cytosolic extracts ovarian tissues (normal, benign, and malignant) by quantitative ELISAs for their ability diagnose, prognose, predict response chemotherapy cancer patients. Experimental Design: Eleven proteins were (9 kallikreins, B7-H4, CA125) 259 tumor tissues, 50 from benign conditions, 35 normal 44 nonovarian tumors that metastasized the ovary. Odds ratios hazard 95% confidence interval...
Sialyl Lewis x (sLex) carbohydrate antigen acts as an adhesion molecule expressed on the surface of cancer cells and is most important ligand selectins present endothelial cells. sLex expression was correlated to metastatic potential breast cancer. The aim work evaluate prognostic value in a series carcinomas with long-term follow-up. A total 127 consecutive patients primary were enrolled followed for median 140 months. Tumor grade, mitotic index, histotype, vascular invasion, tumor...
The superiority of new generation aromatase inhibitors over tamoxifen in the adjuvant treatment early breast carcinoma has emerged from several randomized trials. However, until now not all previous studies have shown a mortality benefit.A pooled analysis 2 prospective multicentric trials, sharing same study design and nearly identical inclusion criteria, was performed. In both women treated previously with for or 3 years were randomly assigned to either continuing an additional having their...
Estrogen synthesis suppression induced by aromatase inhibitors in breast cancer (BC) patients may be affected single nucleotide polymorphisms (SNPs) of the gene encoding enzyme, CYP19A1. We assessed association between plasma estrone sulfate (ES), letrozole treatment, and four SNPs CYP19A1 (rs10046 C>T, rs4646 G>T, rs749292 rs727479 T>G) which seem to related circulating estrogen levels. Patients were enrolled into a prospective, Italian multi-center clinical trial (Gruppo Italiano Mammella,...
Background/Aim: Axillary surgery of breast cancer patients is undergoing a paradigm shift, as axillary lymph node dissection9s (ALND) usefulness being questioned in the treatment with tumor-positive sentinel biopsy (SLNB). The aim this study was to investigate overall survival (OS) and relapse-free (RFS) positive SLNB treated ALND or not. Patients Methods: We investigated 617 consecutive cN0 operable mastectomy conservative surgery. A total 406 underwent 211 were managed expectantly....
Abstract Purpose: In estrogen receptor–positive (ER+) breast cancer, single-nucleotide polymorphisms (SNP) in the aromatase gene might affect inhibitors (AI) metabolism and efficacy. Here, we assessed impact of SNP on prognosis toxicity patients receiving adjuvant letrozole. Experimental Design: We enrolled 886 postmenopausal study. They were treated with letrozole for 2 to 5 years after taking tamoxifen 6 years, continuing until they completed 10 therapy. Germline DNA was genotyped rs4646,...
Obesity is an independent adverse prognostic factor in early breast cancer patients, but it still controversial whether obesity may affect adjuvant endocrine therapy efficacy. The aim of our study (ancillary to the two clinical trials Gruppo Italiano Mammella (GIM)4 and GIM5) was investigate circulating oestrogen levels during treatment with aromatase inhibitor letrozole are related body mass index (BMI) postmenopausal women cancer.Plasma concentration oestrone sulphate (ES) evaluated by...
This study aimed to investigate the feasibility and accuracy of tattooing suspicious axillary lymph nodes with carbon suspension at time breast cancer (BC) diagnosis intraoperative correspondence between tattooed node (TLN) sentinel (SLN) in patients who underwent neoadjuvant chemotherapy (NACT).In this retrospective study, we analyzed consecutive BC NACT, April 2019 May 2021, Breast Unit Sant'Anna Hospital Turin, Italy. Before all biopsied were marked suspension. All SLNs, TLNs, nodal...
555 Background: The CYP19A1 gene encodes aromatase, a key enzyme for estrogen biosynthesis. We investigated the association between four SNPs, affecting different circulating levels (rs10046 C>T, rs4646 G>T, rs749292 rs727479 T>G), and suppression of plasma ES induced by 6 weeks (time needed to reach L steady-state concentrations) (25 mg/d). Methods: Patients were enrolled into prospective, italian multi-centre trial (GIM5) testing correlation SNPs with efficacy adjuvant therapy,...
515 Background: BMI is associated with an increased risk of BC in postmenopausal women. Moreover, overweight women have poorer prognosis compared to normal weight. Data from ATAC (the anastrozole, tamoxifen alone or combination study) trial reported that obesity reduce the efficacy aromatase inhibitor (AI) anastrozole early BC. One possible explanation higher estrogens levels resulting high may lead lower AI treatment. No clear data are available about effects on estrogen circulating during...